Entries by Hannah Thomson

Labs Explorer interviews OracleBio’s Dr Lorcan Sherry

Dr Lorcan Sherry, OracleBio’s Chief Scientific Officer, was recently interviewed by Labs Explorer, an online R&D marketplace that offers a platform for researchers to search for R&D partners, increase visibility and gain financing. In the interview, Lorcan talks about OracleBio’s history and mission as a leading quantitative digital pathology CRO. He also discusses the challenges […]

Keith Bowers joins OracleBio as the Senior Business Development Manager

In line with OracleBio’s vision to drive the adoption and application of digital pathology in R&D, we are thrilled to welcome Dr Keith Bowers as the new Senior Business Development Manager. Applying his 25 years of experience in both scientific and commercial roles within the pharmaceutical industry, Keith joins us to accelerate the company’s growth, […]

6th Digital Pathology & AI Congress 2019

OracleBio will be attending the 6th Digital Pathology & AI Congress, which takes place from the 5th to 6th of December 2019 in London, UK. OracleBio will be exhibiting throughout the meeting. OracleBio is a highly specialised image analysis CRO (contract research organization) providing high precision, quantitative, digital image analysis services to support pre-clinical and […]

Case Study: Clinical R&D

OracleBio contributed to a Clinical R&D program for a global oncology company focused on precision oncology. By utilising multiplex immunofluorescence (IF) and quantitative digital pathology, we supported the researchers in understanding lymphocyte composition within NSCLC tissue by providing quantitative analysis of LAG-3 +ve TIL subsets within tumour microenvironment and determining ratios of dual and triple […]

Case Study: Pre-clinical R&D

OracleBio contributed to a Pre-clinical R&D program for a UK-based drug discovery company with a unique and powerful computer-based drug discovery platform and a specialised approach to network biology. By utilising Immunohistochemistry (IHC) and quantitative digital pathology, we supported the data-driven decision-making process for proof of mechanism studies by providing quantitative and reproducible tissue-based evidence […]

Case Study: Discovery R&D

OracleBio contributed to a Discovery R&D program for a biopharmaceutical company focused on small molecule drugs for oncology. By utilising Tumor Microarrays (TMA) and quantitative digital pathology, we supported the data-driven decision-making process for guiding clinical studies disease selection by leveraging image analysis to quantify the expression of Arginase-1 +ve cells (# mm2) across various […]

Pathology Visions 2019

OracleBio will be attending the Pathology Visions 2019 conference, which takes place from the 6th to 8th of October 2019 in Orlando, Florida. OracleBio will be exhibiting at Booth 318 throughout the meeting. OracleBio is a highly specialised image analysis CRO (contract research organization) providing high precision, quantitative, digital image analysis services to support pre-clinical […]

European Society for Medical Oncology – ESMO Congress 2019

OracleBio will be attending the European Society for Medical Oncology – ESMO Congress 2019, which takes place from the 27th of September to 1st of October 2019 in Barcelona, Spain. OracleBio offers a range of digital pathology services to support pre-clinical and clinical oncology R&D. Using immunohistochemistry and immunoflourescence techniques, we are able to produce […]

34th Annual Meeting & Pre-Conference Programs (SITC 2019)

OracleBio will be attending the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019), which takes place from the 6th to 10th of November 2019 at the Gaylord National Hotel & Convention Center in National Harbor, MD. OracleBio will be exhibiting at Booth 227 throughout the meeting. OracleBio offers […]

OracleBio incorporates Artificial Intelligence (AI) Deep Learning and High Multiplex Image Analysis Technologies to enhance Digital Pathology Capabilities

            Glasgow, UK [16/05/2019]: OracleBio Limited is pleased to announce the integration of Visiopharm’s Artificial Intelligence (AI) deep learning and phenotyping multiplexing modules into its existing Oncotopix® image analysis platform. The Oncotopix® AI deep learning module allows OracleBio to access a range of the most up-to-date deep convolution neural networks […]